(Q42219711)

18 October 2017

Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? (English)

1 reference

18 October 2017

2

Olaf Stüve

1 reference

18 October 2017

1

Gary R Cutter

0 references

publication date

8 May 2014

1 reference

Multiple Sclerosis Journal

18 October 2017

2

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

18 October 2017

20

1 reference

18 October 2017

1304-1305

1 reference

18 October 2017

10

1 reference

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

18 October 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458514531843

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514531843

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514531843

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514531843

21 January 2018

Identifiers

DOI

10.1177/1352458514531843

1 reference

18 October 2017

1 reference

PubMed ID

24812045